212.82MMarket Cap-1.44P/E (TTM)
1.050High0.910Low3.37MVolume0.958Open0.957Pre Close3.37MTurnover1.66%Turnover RatioLossP/E (Static)208.65MShares3.17952wk High5.43P/B206.82MFloat Cap0.30452wk Low--Dividend TTM202.76MShs Float51.375Historical High--Div YieldTTM14.62%Amplitude0.291Historical Low0.998Avg Price1Lot Size
Sangamo Therapeutics Stock Forum
Insiders loading up! Is there something big coming?🤔
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients
3 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR)...
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Thursday, 6th February at 8:05 am
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope obs...
No comment yet